Breast Cancer Clinical Trial

Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer

Summary

This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Breast cancer with evidence of unresectable, locally recurrent or metastatic disease.
Candidate for treatment with paclitaxel.

Exclusion Criteria:

Prior chemotherapy in the advanced disease setting.
HER2 positive disease unless previously treated with trastuzumab.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

22

Study ID:

NCT00174434

Recruitment Status:

Completed

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Pfizer Investigational Site
Harvey Illinois, 60426, United States
Pfizer Investigational Site
Harvey Illinois, 60426, United States
Pfizer Investigational Site
Indianapolis Indiana, 46202, United States
Pfizer Investigational Site
Indianapolis Indiana, 46290, United States
Pfizer Investigational Site
Munster Indiana, 46321, United States
Pfizer Investigational Site
New York New York, 10021, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

22

Study ID:

NCT00174434

Recruitment Status:

Completed

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider